Supernus Pharmaceuticals, Inc. Email Format

Pharmaceutical ManufacturingMaryland, United States501-1000 Employees

Supernus Pharmaceuticals, Inc. is a United States–based biopharmaceutical company in the pharmaceutical manufacturing industry focused on developing and commercializing products for central nervous system diseases. Its approved therapies cover attention-deficit hyperactivity disorder (ADHD), dyskinesia and hypomobility in Parkinson's disease, epilepsy, migraine, cervical dystonia, and chronic sialorrhea, with ongoing development of novel CNS product candidates for epilepsy, depression, and other CNS disorders. The company is headquartered in Rockville, Maryland, operates with roughly 501-1000 employees, and was incorporated in Delaware, began operations in 2005, and started trading publicly in 2012. Supernus' product development expertise spans about 30 years, evolving from a standalone development organization to a U.S. subsidiary of Shire Plc, and later acquiring substantially all assets of Shire Laboratories, Inc. in 2005 as the reorganized company. In recent years, Supernus has expanded its CNS portfolio through acquisitions of the CNS portfolio from US WorldMeds (2020), Adamas Pharmaceuticals (2021), and Sage Therapeutics (2025), and these actions have strengthened its CNS focus and established a position in Women’s Health; the company maintains a portfolio of product brands including Qelbree, Onapgo, GoCovri, Zurzuvae, Trokendixr, Oxtellar XR, Apokyn, Myobloc, and Xadago.

Sign up for free to view info

Company overview Employee directory